DE122010000047I1 - Antikörper gegen opgl - Google Patents
Antikörper gegen opglInfo
- Publication number
- DE122010000047I1 DE122010000047I1 DE122010000047C DE122010000047C DE122010000047I1 DE 122010000047 I1 DE122010000047 I1 DE 122010000047I1 DE 122010000047 C DE122010000047 C DE 122010000047C DE 122010000047 C DE122010000047 C DE 122010000047C DE 122010000047 I1 DE122010000047 I1 DE 122010000047I1
- Authority
- DE
- Germany
- Prior art keywords
- antibodies against
- against opgl
- opgl
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30117201P | 2001-06-26 | 2001-06-26 | |
DE60235989T DE60235989D1 (de) | 2001-06-26 | 2002-06-25 | Antikörper gegen opgl |
Publications (1)
Publication Number | Publication Date |
---|---|
DE122010000047I1 true DE122010000047I1 (de) | 2011-05-05 |
Family
ID=23162250
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60235989T Expired - Lifetime DE60235989D1 (de) | 2001-06-26 | 2002-06-25 | Antikörper gegen opgl |
DE122010000047C Pending DE122010000047I1 (de) | 2001-06-26 | 2002-06-25 | Antikörper gegen opgl |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60235989T Expired - Lifetime DE60235989D1 (de) | 2001-06-26 | 2002-06-25 | Antikörper gegen opgl |
Country Status (33)
Country | Link |
---|---|
US (8) | US7364736B2 (de) |
EP (5) | EP2087908B1 (de) |
JP (13) | JP4212470B2 (de) |
KR (2) | KR101038585B1 (de) |
CN (2) | CN1547486A (de) |
AR (1) | AR034637A1 (de) |
AT (1) | ATE464068T1 (de) |
AU (2) | AU2002320157C1 (de) |
BR (1) | BRPI0210579B8 (de) |
CA (1) | CA2451955C (de) |
CY (5) | CY1110196T1 (de) |
DE (2) | DE60235989D1 (de) |
DK (4) | DK2270052T3 (de) |
EA (1) | EA021242B9 (de) |
ES (5) | ES2342820T5 (de) |
FR (1) | FR10C0050I2 (de) |
HK (1) | HK1187932A1 (de) |
IL (3) | IL159512A0 (de) |
LU (1) | LU91757I2 (de) |
ME (2) | ME00232B (de) |
MX (1) | MXPA04000134A (de) |
MY (1) | MY143582A (de) |
NO (5) | NO345566B1 (de) |
NZ (4) | NZ616594A (de) |
PL (1) | PL222211B1 (de) |
PT (4) | PT2270052T (de) |
RS (1) | RS54274B1 (de) |
SG (3) | SG2011076551A (de) |
TR (3) | TR201900581T4 (de) |
TW (2) | TWI326285B (de) |
WO (1) | WO2003002713A2 (de) |
YU (1) | YU103003A (de) |
ZA (1) | ZA200400521B (de) |
Families Citing this family (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
AU713471C (en) | 1996-12-23 | 2002-04-18 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
DE69834699T3 (de) | 1997-04-15 | 2013-11-14 | Daiichi Sankyo Co., Ltd. | Neues protein und verfahren zu dessen herstellung |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
TR199902512T2 (xx) | 1997-04-16 | 2000-06-21 | Amgen Inc. | Osteoprotegerin ba�lay�c� proteinler ve resept�rler. |
ES2317694T3 (es) | 1998-05-14 | 2009-04-16 | Immunex Corporation | Metodo para inhibir la actividad osteoclastica. |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
DE60129254T2 (de) | 2000-09-22 | 2008-03-13 | Immunex Corp., Thousand Oaks | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
AU2002231368C1 (en) * | 2001-01-05 | 2018-08-16 | Amgen Fremont Inc. | Antibodies to insulin-like growth factor I receptor |
DE60235989D1 (de) * | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen opgl |
US7718776B2 (en) | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
US8420789B2 (en) | 2002-09-11 | 2013-04-16 | Chugai Seiyaku Kabushiki Kaisha | Method for removing DNA contaminants from a protein-containing sample |
EP1479695B1 (de) * | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Humaner monoklonaler Antikörper spezifisch für Lipopolysacchariden (LPS) des Serotyps IATS O6 von Pseudomonas aeruginosa |
ES2321088T3 (es) | 2003-08-08 | 2009-06-02 | Amgen Fremont Inc. | Anticuerpos dirigidos frente a la hormona paratiroidea (pth) y usos de los mismos. |
US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
DK1689777T3 (da) * | 2003-11-05 | 2007-06-11 | Ares Trading Sa | Fremgangsmåde til oprensning af il18-bindende protein |
TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
WO2006015373A2 (en) | 2004-08-04 | 2006-02-09 | Amgen Inc | Antibodies to dkk-1 |
US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
US8129508B2 (en) * | 2005-04-11 | 2012-03-06 | Medarex, Inc. | Protein purification using HCIC and ion exchange chromatography |
AU2015242973C1 (en) * | 2005-06-14 | 2018-07-05 | Amgen Inc. | Self-buffering protein formulations |
KR20080031684A (ko) * | 2005-06-14 | 2008-04-10 | 암젠 인코포레이티드 | 자가 - 완충성 단백질 제형 |
US20070190047A1 (en) * | 2005-07-29 | 2007-08-16 | Amgen, Inc. | Formulations that inhibit protein aggregation |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
WO2007093042A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
US7767451B2 (en) | 2006-04-28 | 2010-08-03 | Kyoritsu Seiyaku Corporation | Feline cell capable of being cultured without animal-derived protein, and method for producing virus and method for producing vaccine using thereof |
UA99262C2 (uk) | 2006-08-28 | 2012-08-10 | Арес Трейдінг С.А. | СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК |
MX2009010179A (es) * | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
KR20120125601A (ko) * | 2007-05-24 | 2012-11-16 | 아블린쓰 엔.브이. | Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
CL2008002444A1 (es) | 2007-08-21 | 2009-09-04 | Amgen Inc | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. |
JP5963341B2 (ja) * | 2007-09-14 | 2016-08-10 | アムジエン・インコーポレーテツド | 均質な抗体集団 |
US8383114B2 (en) | 2007-09-27 | 2013-02-26 | Amgen Inc. | Pharmaceutical formulations |
ES2540733T3 (es) * | 2007-10-11 | 2015-07-13 | Daiichi Sankyo Company, Limited | Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos |
EP2219602A1 (de) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Wässrige formulierung von mit antioxidantien stabilisiertem erythropoese-stimulierendem protein zur parenteralen verabreichung |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
EP2250251B1 (de) | 2008-01-09 | 2017-11-22 | Sartorius Stedim Cellca GmbH | Verbessertes additiv für kulturmedien und verwendungsverfahren dafür |
CN102202643A (zh) * | 2008-02-07 | 2011-09-28 | 安姆根有限公司 | 稳定化的蛋白组合物 |
CL2009001735A1 (es) * | 2008-08-19 | 2010-02-19 | Regeneron Pharma | Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl |
CA2753287A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
CA2753263A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
CA2753332A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
WO2010117011A1 (ja) | 2009-04-09 | 2010-10-14 | 第一三共株式会社 | 抗Siglec-15抗体 |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
EP2531589B1 (de) | 2010-02-01 | 2017-04-05 | MikrobEX | Bakterientherapie für Clostridium-difficile-Colitis |
FI2575935T4 (fi) | 2010-06-07 | 2023-11-23 | Amgen Inc | Lääkeaineen vapautuslaite |
JP5699030B2 (ja) * | 2010-07-05 | 2015-04-08 | Axis株式会社 | エタネルセプトを含む線維筋痛症の治療剤 |
EP2625205A2 (de) | 2010-10-05 | 2013-08-14 | Daiichi Sankyo Company, Limited | Auf das osteoklastenabhängige protein siglec-15 gerichteter antikörper |
MX344315B (es) | 2010-10-06 | 2016-12-13 | Institució Catalana De Recerca I Estudis Avancats | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama. |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
US10092706B2 (en) | 2011-04-20 | 2018-10-09 | Amgen Inc. | Autoinjector apparatus |
EP2702077A2 (de) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen |
RU2661677C2 (ru) | 2011-05-27 | 2018-07-18 | Аблинкс Нв | Ингибирование резорбции кости с помощью связывающих rank-l пептидов |
EP3045188B1 (de) | 2011-10-14 | 2020-12-23 | Amgen Inc. | Injektor und verfahren zur montage |
KR102276161B1 (ko) | 2011-10-25 | 2021-07-14 | 프로테나 바이오사이언시즈 리미티드 | 항체 제형 및 방법 |
WO2013118878A1 (ja) * | 2012-02-09 | 2013-08-15 | 独立行政法人理化学研究所 | 環状rna及びタンパク質の製造方法 |
IN2014DN08215A (de) | 2012-03-30 | 2015-05-15 | Daiichi Sankyo Companyltd | |
EP2650682A1 (de) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
EP2856159A4 (de) * | 2012-06-01 | 2016-04-13 | Momenta Pharmaceuticals Inc | Verfahren im zusammenhang mit denosumab |
CN104603288B (zh) | 2012-06-06 | 2018-12-14 | 生物医学研究机构基金会 | 用于肺癌转移的诊断、预后和治疗的方法 |
EP2875051B1 (de) | 2012-07-19 | 2019-02-20 | Daiichi Sankyo Company, Limited | Antikörper gegen siglec-15 |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
SG10201705668XA (en) | 2012-09-07 | 2017-08-30 | Coherus Biosciences Inc | Stable aqueous formulations of adalimumab |
EP3553186B1 (de) | 2012-10-12 | 2021-11-17 | Inbiomotion, S.L. | Verfahren zur diagnose, prognose und behandlung von prostatakrebsmetastasen |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
CA2884887C (en) | 2012-11-21 | 2023-09-12 | Amgen Inc. | Drug delivery device including insertion member and reservoir |
DK2948553T3 (da) | 2013-01-25 | 2020-06-29 | Baylor College Medicine | Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
EP3593839A1 (de) | 2013-03-15 | 2020-01-15 | Amgen Inc. | Arzneimittelkassette |
US20160032400A1 (en) | 2013-03-15 | 2016-02-04 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
US10092703B2 (en) | 2013-03-15 | 2018-10-09 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
BR112015024282B1 (pt) | 2013-03-22 | 2022-05-17 | Amgen Inc | Injetor e método de montagem do injetor |
WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
US9481901B2 (en) | 2013-05-30 | 2016-11-01 | Amgen Inc. | Methods for increasing mannose content of recombinant proteins |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
HUE040211T2 (hu) | 2013-06-05 | 2019-02-28 | Rebiotix Inc | Mikrobióta-helyreállítási terápia (MRT), készítmények és elõállítási eljárások |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
EP3030249B1 (de) | 2013-08-07 | 2019-12-25 | Rigshospitalet, Copenhagen University Hospital | Antikörper, verbindungen und derivate davon zur verwendung in der behandlung männlicher unfruchtbarkeit |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
US20160207988A1 (en) * | 2013-09-24 | 2016-07-21 | The Board Of Regents Of The University Of Texas System | A novel hormone that promotes bone resorption and uses thereof |
EP3052640A2 (de) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine |
EP3055429B1 (de) | 2013-10-09 | 2019-03-27 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Methode für die prognose und die behandlung von metastasierendem krebs im knochen hervorgegangen aus brustkrebs |
WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
EP3060281B1 (de) | 2013-10-24 | 2019-01-30 | Amgen Inc. | Arzneimittelabgabesystem mit temperaturempfindlicher steuerung |
AU2014340171B2 (en) | 2013-10-24 | 2019-05-30 | Amgen Inc. | Injector and method of assembly |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
RU2656153C1 (ru) * | 2013-12-20 | 2018-05-31 | Девелопмент Сентер Фор Байотекнолоджи | Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии |
CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
ES2784749T3 (es) | 2014-03-10 | 2020-09-30 | Richter Gedeon Nyrt | Purificación de inmunoglobulina con el uso de etapas de limpieza previa |
WO2015171777A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
CN106488782B (zh) | 2014-06-03 | 2021-03-09 | 安姆根有限公司 | 用于辅助药物递送装置的用户的装置和方法 |
KR102391259B1 (ko) * | 2014-06-04 | 2022-04-26 | 암젠 인크 | 포유류 세포 배양물을 회수하는 방법 |
AU2015332557B2 (en) | 2014-10-14 | 2020-05-14 | Amgen Inc. | Drug injection device with visual and audio indicators |
CN107001480B (zh) | 2014-12-11 | 2021-12-03 | 生物运动有限公司 | 用于人c-maf的结合成员 |
WO2016100055A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with live button or user interface field |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
US10583245B2 (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
US10111928B1 (en) * | 2015-02-25 | 2018-10-30 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta |
US10328123B2 (en) | 2015-02-25 | 2019-06-25 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis |
US10745461B2 (en) | 2015-02-25 | 2020-08-18 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis |
JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
EP4039253A1 (de) | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Verfahren zur behandlung von krebs |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
JP6616431B2 (ja) | 2015-06-09 | 2019-12-04 | レビオティクス インコーポレイテッド | マイクロバイオータ回復治療(mrt)組成物の製造方法 |
HU231463B1 (hu) | 2015-08-04 | 2024-01-28 | Richter Gedeon Nyrt. | Módszer rekombináns proteinek galaktóz tartalmának növelésére |
MA42613A (fr) | 2015-08-13 | 2018-06-20 | Amgen Inc | Filtration en profondeur chargée de protéines de liaison à un antigène |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
AU2017229575A1 (en) | 2016-03-08 | 2018-09-27 | Janssen Biotech, Inc. | GITR antibodies, methods, and uses |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
KR20230128144A (ko) | 2016-05-25 | 2023-09-01 | 인바이오모션 에스.엘. | c-MAF 상태에 기초한 유방암의 치료 |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
BR112019007858A2 (pt) | 2016-10-21 | 2019-07-02 | Amgen Inc | formulações farmacêuticas e métodos para produzir as mesmas |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
KR102322802B1 (ko) | 2017-01-05 | 2021-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
WO2018136398A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
WO2018152073A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
US11752258B2 (en) | 2017-02-17 | 2023-09-12 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
MX2019010544A (es) | 2017-03-06 | 2019-10-21 | Amgen Inc | Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion. |
US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
MX2019010671A (es) | 2017-03-09 | 2019-10-21 | Amgen Inc | Mecanismo de insercion para dispositivo de administracion de farmacos. |
MX2019011416A (es) | 2017-03-28 | 2019-11-01 | Amgen Inc | Sistema y metodo para conjunto de jeringa y vastago de embolo. |
JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
EP3618871A4 (de) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | Formulierungen von anti-lag3-antikörpern und co-formulierungen von anti-lag3-antikörpern und anti-pd-1-antikörpern |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
EP3634539A1 (de) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Spritzenanordnung für eine wirkstofffreisetzungsvorrichtung und verfahren zur montage |
AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
MA49461A (fr) | 2017-06-23 | 2020-04-29 | Amgen Inc | Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
EP4085942A1 (de) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Arzneimittelabgabevorrichtung mit getriebemodul und verwandtes verfahren zur montage |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
EP3691716B1 (de) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren |
EP3694578A1 (de) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Arzneimittelabgabevorrichtung mit antriebsanordnung sowie zugehöriges verfahren zur montage |
EP3703778A1 (de) | 2017-11-03 | 2020-09-09 | Amgen Inc. | System und ansätze zum sterilisieren einer arzneimittelabgabevorrichtung |
JP2021501616A (ja) | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | 配置及び流量検出を備える薬物送達デバイス |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
JP7247174B2 (ja) | 2017-11-10 | 2023-03-28 | アムジエン・インコーポレーテツド | 薬物送達デバイスのプランジャ |
CA3084486A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
AU2018368340B2 (en) | 2017-11-16 | 2024-03-07 | Amgen Inc. | Door latch mechanism for drug delivery device |
EP3713581A1 (de) | 2017-11-22 | 2020-09-30 | Inbiomotion S.L. | Therapeutische behandlung von brustkrebs auf der basis des c-maf |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
CN112423844A (zh) | 2018-07-04 | 2021-02-26 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
CN112469454B (zh) | 2018-07-24 | 2024-01-26 | 安进公司 | 用于施用药物的输送装置 |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
MX2021000749A (es) | 2018-07-24 | 2021-03-29 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
IL281469B1 (en) | 2018-09-28 | 2024-04-01 | Amgen Inc | Assembling a memory alloy ejector activation assembly for a drug delivery device |
AR116679A1 (es) | 2018-10-02 | 2021-06-02 | Amgen Inc | Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna |
EP3860686A1 (de) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Medikamentenabgabevorrichtung mit dosisindikator |
KR20210076935A (ko) | 2018-10-15 | 2021-06-24 | 암젠 인크 | 댐핑 메커니즘을 갖는 약물 전달 장치 |
TW202031306A (zh) | 2018-10-15 | 2020-09-01 | 美商安進公司 | 用於藥物遞送裝置之平台組裝方法 |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
WO2020092056A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial needle retraction |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
HUP1800376A2 (hu) | 2018-11-07 | 2020-05-28 | Richter Gedeon Nyrt | Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer |
HUP1900112A1 (hu) | 2019-04-04 | 2020-10-28 | Richter Gedeon Nyrt | Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelõzõ flokkulálás alkalmazásával |
JP2022529319A (ja) | 2019-04-24 | 2022-06-21 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
US20220195059A1 (en) | 2019-04-30 | 2022-06-23 | Instituto de Medicina Molecular João Lobo Antunes | Rank Pathway Inhibitors in Combination with CDK Inhibitors |
JP2022545227A (ja) | 2019-08-23 | 2022-10-26 | アムジエン・インコーポレーテツド | 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法 |
WO2021149012A1 (en) | 2020-01-24 | 2021-07-29 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
CN113621060B (zh) * | 2020-05-07 | 2023-07-04 | 浙江瑞硕生物技术有限公司 | 一种opg抗体对及其应用 |
EP4341161A1 (de) | 2021-05-21 | 2024-03-27 | Amgen Inc. | Verfahren zur optimierung eines füllrezepts für einen arzneimittelbehälter |
WO2024064878A1 (en) | 2022-09-23 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of melanoma |
Family Cites Families (290)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
US4710457A (en) * | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US4760130A (en) | 1984-12-06 | 1988-07-26 | Synergen Biologicals, Inc. | Serine protease inhibitors and methods for isolation of same |
US5900400A (en) | 1984-12-06 | 1999-05-04 | Amgen Inc. | Serine protease inhibitor analogs |
JPS6291197A (ja) | 1985-10-17 | 1987-04-25 | Dainippon Pharmaceut Co Ltd | 抗ヒトインタ−ロイキン1抗体,その製法及びその使用法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5359032A (en) | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5811261A (en) | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
EP0364778B1 (de) | 1988-10-01 | 1996-03-13 | Otsuka Pharmaceutical Co., Ltd. | Antikörper gegen Interleukin-1-beta |
FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0393438B1 (de) | 1989-04-21 | 2005-02-16 | Amgen Inc. | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
IL107267A (en) | 1993-10-12 | 2009-07-20 | Yeda Res & Dev | Ligand to a member of the tnf/ngf receptor family |
CA2017025C (en) | 1989-05-18 | 2008-07-22 | David Wallach | Tumor necrosis factor binding protein ii, its purification and antibodies thereto |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
BR9007883A (pt) | 1989-11-29 | 1992-09-29 | Synergen Inc | Producao de inibidor de interleucina-1 humana recombinante |
CA2032191C (en) | 1989-12-13 | 1999-05-18 | David Wallach | Expression of the recombinant tumor necrosis factor binding protein i (tbp-i) |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
AU649245B2 (en) | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
AU7683391A (en) | 1990-04-27 | 1991-11-27 | Upjohn Company, The | Modified interleukin-1 inhibitors |
ATE178094T1 (de) | 1990-05-01 | 1999-04-15 | Chiron Corp | Interleukin-i antagonist und seine verwendung |
US5872095A (en) | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
EP0835939B8 (de) | 1990-06-28 | 2006-01-11 | Sanofi-Aventis Deutschland GmbH | Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung |
WO1992001002A1 (fr) | 1990-07-11 | 1992-01-23 | Teijin Limited | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
ATE161720T1 (de) | 1990-08-03 | 1998-01-15 | Smithkline Beecham Corp | Tnf-inhibitoren |
US5824549A (en) | 1990-10-09 | 1998-10-20 | Chiron Corporation | Transformed human T cell |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5858355A (en) | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
NZ314630A (en) | 1991-01-17 | 2000-11-24 | Harvard College | Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell |
RU2166955C2 (ru) | 1991-01-18 | 2001-05-20 | Эмген Инк. | Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток |
ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US5770401A (en) | 1991-10-15 | 1998-06-23 | Mullarkey; Michael F. | Methods and compositions for treating allergic reactions |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
ES2038546B1 (es) | 1991-11-08 | 1994-02-16 | Andromaco Lab | Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral. |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
AU669702B2 (en) | 1992-03-04 | 1996-06-20 | Cell Therapeutics, Inc. | Enantiomeric hydroxylated xanthine compounds |
ATE242322T1 (de) | 1992-03-30 | 2003-06-15 | Immunex Corp | Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält |
DK0639079T3 (da) | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
DE4219626A1 (de) | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen |
JPH0630788A (ja) | 1992-07-16 | 1994-02-08 | Otsuka Pharmaceut Co Ltd | ヒトインターロイキン−1に対する組換え抗体 |
US5545716A (en) | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
RU2126262C1 (ru) | 1992-09-17 | 1999-02-20 | Амген Боулдер Инк. | Фармацевтическая композиция |
JPH06111399A (ja) | 1992-09-30 | 1994-04-22 | Sony Corp | 光磁気記録媒体及びその製造方法 |
CA2146126A1 (en) | 1992-10-07 | 1994-04-14 | Kenji Irie | Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor |
US5891438A (en) * | 1992-10-30 | 1999-04-06 | The Regents Of The University Of California | Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination |
US5866576A (en) | 1992-12-16 | 1999-02-02 | Cell Therapeutics, Inc. | Epoxide-containing compounds |
ES2124801T3 (es) | 1993-01-08 | 1999-02-16 | Hoechst Ag | Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa. |
ATE204299T1 (de) | 1993-03-05 | 2001-09-15 | Bayer Ag | Humane monoklonale anti-tnf alpha antikörper |
WO1994020517A1 (en) | 1993-03-08 | 1994-09-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for treating a connective tissue of a mammalian host |
DE69431620T2 (de) | 1993-03-19 | 2003-07-03 | Vacsyn Sa | Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US5843905A (en) | 1993-06-04 | 1998-12-01 | Vertex Pharmaceuticals, Incorporated | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors |
FR2706772A1 (en) | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
PT711282E (pt) | 1993-07-28 | 2002-11-29 | Aventis Pharma Ltd | Compostos inibidores de pde iv e de fnt |
CA2175458C (en) | 1993-11-29 | 1999-03-02 | Boyd L. Harrison | Novel benzenesulfonylimine derivatives as inhibitors of il-1 action |
CA2138305A1 (en) | 1993-12-28 | 1995-06-29 | Naohito Ohashi | Tumor necrosis factor production inhibitors |
GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
DE69503769T2 (de) | 1994-03-09 | 1998-12-03 | Pfizer | Isoxazoline verbindung zur hemmung tnf-freigabe |
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
US5817822A (en) | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
IL114417A0 (en) | 1994-07-07 | 1995-10-31 | Res Dev Foundation | Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use |
US5877180A (en) | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Hayashibara Biochem Lab | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
US5641747A (en) | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
US5633227A (en) | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
DK0784629T3 (da) | 1994-10-05 | 1999-10-25 | Darwin Discovery Ltd | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser |
US5852173A (en) | 1994-10-19 | 1998-12-22 | Genetics Institute, Inc. | TNF receptor death ligand proteins and inhibitors of ligand binding |
TW581771B (en) | 1994-11-15 | 2004-04-01 | Hayashibara Biochem Lab | Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide |
ZA9510826B (en) | 1994-12-23 | 1996-06-20 | Smithkline Beecham Corp | 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds |
US5863926A (en) | 1994-12-23 | 1999-01-26 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
KR19980701286A (ko) | 1995-01-09 | 1998-05-15 | 오스카 아키히코 | Tnf-알파 억제제 |
PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
HUP9800049A3 (en) | 1995-02-23 | 1999-01-28 | Novartis Nutrition Ag | Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf |
WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
EP0737471A3 (de) | 1995-04-10 | 2000-12-06 | L'oreal | Verwendung von Erdalkalimetallsalze als TNF-alpha Inhibitor in einer topischen Zusammensetzung und die so hergestellte Zusammensetzung |
PT821671E (pt) | 1995-04-20 | 2001-04-30 | Pfizer | Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf |
AU706064B2 (en) | 1995-05-10 | 1999-06-10 | Darwin Discovery Limited | Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use |
AR004471A1 (es) | 1995-05-31 | 1998-12-16 | Smithkline Beecham Corp | Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen |
US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5830742A (en) | 1995-06-08 | 1998-11-03 | Immunex Corporation | TNF-α converting enzyme |
DE69635480T2 (de) | 1995-06-29 | 2006-08-17 | Immunex Corp., Thousand Oaks | Apoptosis induzierendes cytokin |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
ZA966663B (en) | 1995-08-17 | 1998-02-06 | Genentech Inc | Traf Inhibitors. |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
WO1997008174A1 (en) | 1995-08-31 | 1997-03-06 | Smithkline Beecham Corporation | Interleukin converting enzyme and apoptosis |
IL115245A (en) | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
WO1997012244A1 (en) | 1995-09-27 | 1997-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining t-cell profiles of immunocompromised subjects |
DK0859784T3 (da) | 1995-10-05 | 2003-04-22 | Darwin Discovery Ltd | Thiosubstituerede peptider som inhibitorer af metalloproteinaser og TNF-frigivelse |
DE19540475A1 (de) | 1995-10-20 | 1997-04-24 | Schering Ag | Chirale Methylphenyloxazolidinone |
US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
CA2237524A1 (en) | 1995-11-14 | 1997-05-22 | Du Pont Pharmaceuticals Company | Novel macrocyclic compounds as metalloprotease inhibitors |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CO4750805A1 (es) * | 1995-12-13 | 1999-03-31 | Sumitomo Chemical Co | Compuesto para champu |
US5869315A (en) | 1995-12-18 | 1999-02-09 | Basf Aktiengesellschaft | Modified interleukin-1β converting enzyme with increased stability |
US5891883A (en) | 1995-12-21 | 1999-04-06 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds |
US5990119A (en) | 1995-12-21 | 1999-11-23 | Smithkline Beecham Corporation | 1,4,4-(trisubstituted)cyclohexane monomers and related compounds |
US5869677A (en) | 1995-12-21 | 1999-02-09 | Smithkline Beecham Corporation | 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
WO1997024441A1 (en) | 1995-12-29 | 1997-07-10 | Incyte Pharmaceuticals, Inc. | Nucleic acids encoding interferon gamma inducing factor-2 |
US6046048A (en) | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
TR199801532T2 (xx) | 1996-02-09 | 1998-11-23 | Basf Aktiengesellschaft | �nsan TNFalfa 's�n� ba�layan insan antikorlar�. |
HU230160B1 (hu) | 1996-02-09 | 2015-09-28 | Swedish Orphan Biovitrum Ab (Publ) | Interleukin-I inhibitort és kontrollált felszabadulású polimerként hialuronant tartalmazó készítmények |
US5994351A (en) | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
US5981220A (en) | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
GB9607249D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9607120D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9607119D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
US5710013A (en) | 1996-04-19 | 1998-01-20 | Tularik Inc. | Tumor necrosis factor receptor associated factor 6 (TRAF6) |
GB9609795D0 (en) | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
AUPO048296A0 (en) | 1996-06-14 | 1996-07-11 | Fujisawa Pharmaceutical Co., Ltd. | New compound and its preparation |
EP0816499A3 (de) | 1996-06-27 | 1999-10-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomische DNS, die für ein Polypeptid kodiert welches die Fähigkeit besitzt die Interferon-Gamma Herstellung zu induzieren |
DE69700616T2 (de) | 1996-07-02 | 2000-03-16 | Nisshin Flour Milling Co | Imid derivate |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US5853977A (en) | 1996-07-12 | 1998-12-29 | Schering Corporation | Mammalian TNF-α convertases |
JPH10130149A (ja) | 1996-07-12 | 1998-05-19 | Sankyo Co Ltd | Tnf産生抑制剤 |
US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
GB9616643D0 (en) | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
EP0918746B1 (de) | 1996-08-12 | 2003-04-09 | Celgene Corporation | Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte |
US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
ES2217428T3 (es) | 1996-09-25 | 2004-11-01 | Ss Pharmaceutical Co., Ltd. | Derivados de vinilpiridina sustituidos y medicamentos que los contienen. |
US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
GB9621859D0 (en) | 1996-10-21 | 1996-12-11 | Xenova Ltd | Cytokine production inhibitors |
GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
JPH10147531A (ja) | 1996-11-19 | 1998-06-02 | Otsuka Pharmaceut Co Ltd | TNF−α産生抑制剤 |
WO1998021957A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
US5955480A (en) | 1996-11-20 | 1999-09-21 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
US5834435A (en) | 1996-11-27 | 1998-11-10 | Slesarev; Vladimir I. | Inhibition of TNF-α pleiotropic and cytotoxic effects |
CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
PT942740E (pt) | 1996-12-06 | 2004-01-30 | Amgen Inc | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf |
DE19652227A1 (de) | 1996-12-16 | 1998-06-18 | Bosch Gmbh Robert | Verfahren und Vorrichtung zum Zuordnen einer Fernbedienung zu einer Basisstation |
JPH10231285A (ja) | 1996-12-17 | 1998-09-02 | Ishihara Sangyo Kaisha Ltd | フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
AU713471C (en) | 1996-12-23 | 2002-04-18 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
ZA9818B (en) | 1997-01-07 | 1998-07-02 | Abbott Lab | C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion |
US5952320A (en) | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
US6054559A (en) | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
HUP0000567A3 (en) | 1997-01-29 | 2002-10-28 | Pfizer | Sulfonyl urea derivatives and pharmaceutical compositions thereof inhibiting interleukin-1 activity |
JP3955352B2 (ja) * | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US6476027B1 (en) | 1997-03-04 | 2002-11-05 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
CA2282399A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Thioaryl sulfonamide hydroxamic acid compounds |
CN1105114C (zh) | 1997-03-04 | 2003-04-09 | 孟山都公司 | 芳族磺酰基α-羟基异羟肟酸化合物 |
US6638952B1 (en) | 1997-03-04 | 2003-10-28 | Pharmacia Corporation | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
US6087116A (en) | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
JPH10259140A (ja) | 1997-03-18 | 1998-09-29 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生抑制剤 |
ID22975A (id) | 1997-03-18 | 1999-12-23 | Basf Ag | Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid |
US6054487A (en) | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
AU6769298A (en) | 1997-03-21 | 1998-10-20 | Cistron Biotechnology, Inc. | Method for inhibiting cleavage of precursor il-1beta |
GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
WO1998043959A1 (en) | 1997-03-28 | 1998-10-08 | Zeneca Limited | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
EP0971881A1 (de) | 1997-03-28 | 2000-01-19 | AstraZeneca AB | Verfahren zur herstellung von n-(3-hydroxy-succinyl) amino säure derivaten |
TR199902432T2 (xx) | 1997-04-04 | 2000-01-21 | Prizer Products Inc. | Nikotinamid t�revleri. |
CN1262625A (zh) | 1997-04-10 | 2000-08-09 | 阿吉尼克斯股份有限公司 | 乳铁蛋白在治疗过敏原诱发疾病中的应用 |
DE69834699T3 (de) * | 1997-04-15 | 2013-11-14 | Daiichi Sankyo Co., Ltd. | Neues protein und verfahren zu dessen herstellung |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
TR199902512T2 (xx) * | 1997-04-16 | 2000-06-21 | Amgen Inc. | Osteoprotegerin ba�lay�c� proteinler ve resept�rler. |
FR2762315B1 (fr) | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
JP2001522357A (ja) | 1997-04-24 | 2001-11-13 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 炎症性疾患の治療に有用な置換イミダゾール |
FR2762514B1 (fr) | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Icam−1産生阻害剤 |
JP2002502379A (ja) | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | p38キナーゼインヒビターとしての3(5)−ヘテロアリール置換ピラゾール |
US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
JPH111481A (ja) | 1997-06-10 | 1999-01-06 | Sumitomo Pharmaceut Co Ltd | ピペリジニルフタラジン誘導体 |
AU742293B2 (en) | 1997-06-12 | 2001-12-20 | Aventis Pharma Limited | Imidazolyl-cyclic acetals |
KR19990001101A (ko) | 1997-06-12 | 1999-01-15 | 손경식 | 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물 |
WO1998056377A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
GB9713732D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Substituted triazinic compounds |
GB9713733D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Poly-branched polycarboxamido compounds |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
US6235787B1 (en) | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
WO1999003837A1 (en) | 1997-06-30 | 1999-01-28 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
AU8280798A (en) | 1997-07-03 | 1999-01-25 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
US5843721A (en) | 1997-07-03 | 1998-12-01 | Tularik Inc. | Nucleic acids encoding human NIK protein |
WO1999002510A1 (en) | 1997-07-10 | 1999-01-21 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
DE19731521A1 (de) | 1997-07-23 | 1999-01-28 | Byk Gulden Lomberg Chem Fab | Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems |
FR2766822B1 (fr) | 1997-07-30 | 2001-02-23 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AR016551A1 (es) | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
RU2199530C2 (ru) | 1997-07-31 | 2003-02-27 | Селджин Корпорейшн | ЗАМЕЩЕННЫЕ ГИДРОКСАМОВЫЕ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ TNFα |
EP1003751A1 (de) | 1997-08-04 | 2000-05-31 | Amgen Inc. | Hydroxamsäure substituierte kondensierte heterocyclische metalloproteinase inhibitoren |
EP1009752B1 (de) | 1997-08-04 | 2007-03-07 | Millennium Pharmaceuticals, Inc. | Neue moleküle aus der familie der tango-77-ähnlichen proteine und ihre verewendungen. |
CN1158281C (zh) | 1997-08-06 | 2004-07-21 | 第一三得利制药株式会社 | 作为iv型磷酸二酯酶抑制剂的1-芳基-1,8-二氮杂萘-4-酮衍生物 |
EP0895988B1 (de) | 1997-08-08 | 2002-05-22 | Pfizer Products Inc. | Arylsulfonylaminohydroxamsäurederivate |
WO1999007679A1 (en) | 1997-08-08 | 1999-02-18 | Chiroscience Limited | Peptidyl compounds having mmp and tnf inhibitory activity |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US5994396A (en) | 1997-08-18 | 1999-11-30 | Centaur Pharmaceuticals, Inc. | Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
WO1999009965A2 (en) | 1997-08-21 | 1999-03-04 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
JP2001521906A (ja) | 1997-11-03 | 2001-11-13 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 血管新生を阻害し、癌を処置するための方法及び組成物 |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
ZA99252B (en) | 1998-01-16 | 1999-07-14 | Centaur Pharmaceuticals Inc | Thioether furan nitrone compounds. |
JP2002509153A (ja) | 1998-01-20 | 2002-03-26 | ワーナー−ランバート・カンパニー | インターロイキン−1β変換酵素(ICE)のインビボ阻害剤としてのN−[2−(5−ベンジルオキシカルボニル−アミノ−6−オキソ−2−(4−フルオロフェニル)−1,6−ジヒドロ−1−ピリミジニル)アセトキシル]−L−アスパラギン酸アルデヒド |
CA2318030C (en) | 1998-01-23 | 2009-02-17 | Immunex Corporation | Acpl dna and polypeptides |
JP4271850B2 (ja) | 1998-01-23 | 2009-06-03 | イミュネックス・コーポレーション | Il−18受容体 |
AU2472899A (en) | 1998-01-27 | 1999-08-09 | Millennium Pharmaceuticals, Inc. | Novel molecules of the tnf receptor superfamily and uses therefor |
IL137162A0 (en) | 1998-01-27 | 2001-07-24 | American Cyanamid Co | 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors |
AU2901899A (en) | 1998-03-09 | 1999-09-27 | Vertex Pharmaceuticals Incorporated | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
EP1076563B1 (de) | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptid kaspase inhibitoren und deren verwendung |
UA74133C2 (uk) | 1998-03-19 | 2005-11-15 | Вертекс Фармасьютикалс Інкорпорейтед | Інгібітор каспаз, фармацевтична композиція на його основі та спосіб лікування чи профілактики захворювання |
IL126024A0 (en) | 1998-03-19 | 1999-05-09 | Yeda Res & Dev | Modulators of the function of receptors of the tnf/ngf receptor family and other proteins |
ATE317691T1 (de) | 1998-03-20 | 2006-03-15 | Daiichi Asubio Pharma Co Ltd | Benzochinonderivate enthaltende hemmer von nf-kb |
WO1999050238A1 (fr) | 1998-03-26 | 1999-10-07 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives d'uree |
ES2317694T3 (es) | 1998-05-14 | 2009-04-16 | Immunex Corporation | Metodo para inhibir la actividad osteoclastica. |
CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
KR100537558B1 (ko) | 1998-09-01 | 2005-12-19 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 인터류킨-18 결합 단백질 |
SK3062001A3 (en) | 1998-09-15 | 2002-02-05 | Pharmexa As | Method for down-regulating osteoprotegerin ligand activity |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
SI1141028T1 (sl) * | 1998-12-23 | 2010-05-31 | Pfizer | Človeška monoklonska protitelesa proti CTLA |
CA2640956C (en) | 1999-02-03 | 2012-07-03 | Amgen Inc. | B7rp-1 polypeptides |
WO2000047740A2 (en) | 1999-02-12 | 2000-08-17 | Amgen Inc. | Tnf-related proteins |
AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
EP1238077A1 (de) | 1999-12-16 | 2002-09-11 | Amgen Inc., | Tnfr/opg-ähnliches protein und dessen verwendungen |
CA2400929C (en) † | 2000-02-23 | 2011-05-31 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
JP2003533187A (ja) | 2000-05-03 | 2003-11-11 | アムジエン・インコーポレーテツド | 治療薬としてのFcドメインを含む修飾ペプチド |
US7102050B1 (en) | 2000-05-04 | 2006-09-05 | Exxonmobil Chemical Patents Inc. | Multiple riser reactor |
US20030215450A1 (en) * | 2000-05-26 | 2003-11-20 | Blake Simon M | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
US7405734B2 (en) * | 2000-07-18 | 2008-07-29 | Silicon Graphics, Inc. | Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units |
DE10039710B4 (de) | 2000-08-14 | 2017-06-22 | United Monolithic Semiconductors Gmbh | Verfahren zur Herstellung passiver Bauelemente auf einem Halbleitersubstrat |
US20040247596A1 (en) * | 2000-08-18 | 2004-12-09 | Odgren Paul R. | TRANCE regulation of chondrocyte differentiation |
AU2001288342A1 (en) | 2000-08-21 | 2002-03-04 | Smith Kline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
AU2002231368C1 (en) | 2001-01-05 | 2018-08-16 | Amgen Fremont Inc. | Antibodies to insulin-like growth factor I receptor |
JP2004536056A (ja) | 2001-05-17 | 2004-12-02 | イミュネックス・コーポレーション | Rankアンタゴニストの療法使用 |
EP1432438A2 (de) | 2001-06-06 | 2004-06-30 | Immunex Corporation | Verwendung von rang-antagonisten zur behandlung von krebs |
DE60235989D1 (de) | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen opgl |
US7718776B2 (en) * | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
JP5782185B2 (ja) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2002
- 2002-06-25 DE DE60235989T patent/DE60235989D1/de not_active Expired - Lifetime
- 2002-06-25 DK DK10181323.6T patent/DK2270052T3/en active
- 2002-06-25 TR TR2019/00581T patent/TR201900581T4/tr unknown
- 2002-06-25 EP EP09156995.4A patent/EP2087908B1/de not_active Expired - Lifetime
- 2002-06-25 EP EP02749660.3A patent/EP1409016B9/de not_active Expired - Lifetime
- 2002-06-25 NZ NZ616594A patent/NZ616594A/en not_active IP Right Cessation
- 2002-06-25 DK DK10185344.8T patent/DK2295081T3/en active
- 2002-06-25 PT PT101813236T patent/PT2270052T/pt unknown
- 2002-06-25 EP EP10185344.8A patent/EP2295081B1/de not_active Expired - Lifetime
- 2002-06-25 TR TR2018/09678T patent/TR201809678T4/tr unknown
- 2002-06-25 PL PL371915A patent/PL222211B1/pl unknown
- 2002-06-25 NZ NZ547695A patent/NZ547695A/en not_active IP Right Cessation
- 2002-06-25 YU YU103003A patent/YU103003A/sh unknown
- 2002-06-25 PT PT91569954T patent/PT2087908T/pt unknown
- 2002-06-25 CN CNA028166809A patent/CN1547486A/zh active Pending
- 2002-06-25 DE DE122010000047C patent/DE122010000047I1/de active Pending
- 2002-06-25 EA EA200400063A patent/EA021242B9/ru active Protection Beyond IP Right Term
- 2002-06-25 AT AT02749660T patent/ATE464068T1/de active
- 2002-06-25 CN CN201310052370.5A patent/CN103232539B/zh not_active Expired - Lifetime
- 2002-06-25 SG SG2011076551A patent/SG2011076551A/en unknown
- 2002-06-25 RS RS20120347A patent/RS54274B1/en unknown
- 2002-06-25 SG SG2005081195A patent/SG173211A1/en unknown
- 2002-06-25 KR KR1020107002067A patent/KR101038585B1/ko active Protection Beyond IP Right Term
- 2002-06-25 PT PT10185344T patent/PT2295081T/pt unknown
- 2002-06-25 ME MEP-2008-326A patent/ME00232B/me unknown
- 2002-06-25 ES ES02749660T patent/ES2342820T5/es not_active Expired - Lifetime
- 2002-06-25 BR BR0210579-9 patent/BRPI0210579B8/pt not_active IP Right Cessation
- 2002-06-25 NO NO20200535A patent/NO345566B1/no not_active IP Right Cessation
- 2002-06-25 IL IL15951202A patent/IL159512A0/xx unknown
- 2002-06-25 TR TR2018/09008T patent/TR201809008T4/tr unknown
- 2002-06-25 ME MEP-326/08A patent/MEP32608A/xx unknown
- 2002-06-25 WO PCT/US2002/020181 patent/WO2003002713A2/en active Application Filing
- 2002-06-25 ES ES09156995.4T patent/ES2675735T3/es not_active Expired - Lifetime
- 2002-06-25 NZ NZ530765A patent/NZ530765A/en not_active IP Right Cessation
- 2002-06-25 ES ES18202340T patent/ES2907826T3/es not_active Expired - Lifetime
- 2002-06-25 ES ES10181323.6T patent/ES2674888T3/es not_active Expired - Lifetime
- 2002-06-25 US US10/180,648 patent/US7364736B2/en not_active Expired - Lifetime
- 2002-06-25 DK DK02749660.3T patent/DK1409016T4/da active
- 2002-06-25 AU AU2002320157A patent/AU2002320157C1/en active Active
- 2002-06-25 MX MXPA04000134A patent/MXPA04000134A/es active IP Right Grant
- 2002-06-25 KR KR10-2003-7017009A patent/KR20040023630A/ko active Search and Examination
- 2002-06-25 CA CA2451955A patent/CA2451955C/en not_active Expired - Lifetime
- 2002-06-25 DK DK09156995.4T patent/DK2087908T3/en active
- 2002-06-25 JP JP2003509075A patent/JP4212470B2/ja not_active Expired - Lifetime
- 2002-06-25 EP EP18202340.8A patent/EP3492100B1/de not_active Expired - Lifetime
- 2002-06-25 PT PT02749660T patent/PT1409016E/pt unknown
- 2002-06-25 SG SG10201603108QA patent/SG10201603108QA/en unknown
- 2002-06-25 MY MYPI20022368A patent/MY143582A/en unknown
- 2002-06-25 ES ES10185344T patent/ES2706902T3/es not_active Expired - Lifetime
- 2002-06-25 EP EP10181323.6A patent/EP2270052B8/de not_active Expired - Lifetime
- 2002-06-26 AR ARP020102401A patent/AR034637A1/es active IP Right Grant
- 2002-06-26 TW TW095103780A patent/TWI326285B/zh not_active IP Right Cessation
- 2002-06-26 TW TW091114055A patent/TWI276443B/zh active
-
2003
- 2003-12-22 IL IL159512A patent/IL159512A/en active IP Right Grant
-
2004
- 2004-01-23 ZA ZA200400521A patent/ZA200400521B/xx unknown
- 2004-03-10 NO NO20041018A patent/NO343687B1/no not_active IP Right Cessation
-
2005
- 2005-06-25 NZ NZ581637A patent/NZ581637A/en not_active IP Right Cessation
-
2007
- 2007-10-30 US US11/981,664 patent/US8058418B2/en not_active Expired - Lifetime
-
2008
- 2008-07-04 JP JP2008175541A patent/JP4358282B2/ja not_active Expired - Lifetime
- 2008-12-19 AU AU2008261137A patent/AU2008261137C1/en active Active
-
2009
- 2009-07-08 JP JP2009161406A patent/JP4927910B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-08 CY CY20101100637T patent/CY1110196T1/el unknown
- 2010-11-24 LU LU91757C patent/LU91757I2/fr unknown
- 2010-11-24 CY CY2010016C patent/CY2010016I1/el unknown
- 2010-11-25 FR FR10C0050C patent/FR10C0050I2/fr active Active
-
2011
- 2011-11-14 US US13/296,201 patent/US8409578B2/en not_active Expired - Lifetime
-
2012
- 2012-01-17 JP JP2012006740A patent/JP5065529B2/ja not_active Expired - Lifetime
- 2012-03-23 JP JP2012066632A patent/JP2012153701A/ja not_active Withdrawn
- 2012-07-02 JP JP2012148656A patent/JP5576903B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/831,099 patent/US20140134157A1/en not_active Abandoned
-
2014
- 2014-02-05 HK HK14101098.3A patent/HK1187932A1/xx not_active IP Right Cessation
- 2014-10-19 IL IL235116A patent/IL235116A0/en unknown
- 2014-10-28 JP JP2014218929A patent/JP2015057408A/ja active Pending
- 2014-11-27 JP JP2014239576A patent/JP2015078205A/ja active Pending
-
2015
- 2015-02-12 US US14/621,072 patent/US20150266952A1/en not_active Abandoned
-
2016
- 2016-06-07 JP JP2016113389A patent/JP2016216464A/ja active Pending
- 2016-09-02 US US15/256,194 patent/US20170183417A1/en not_active Abandoned
-
2017
- 2017-12-25 JP JP2017247287A patent/JP2018154614A/ja not_active Ceased
-
2018
- 2018-06-26 CY CY181100655T patent/CY1120656T1/el unknown
- 2018-07-17 CY CY181100747T patent/CY1120658T1/el unknown
-
2019
- 2019-01-21 CY CY20191100079T patent/CY1121151T1/el unknown
- 2019-04-04 NO NO20190456A patent/NO344842B1/no not_active IP Right Cessation
- 2019-06-10 JP JP2019107837A patent/JP2019214563A/ja active Pending
- 2019-11-05 NO NO2019039C patent/NO2019039I1/no unknown
- 2019-12-20 NO NO2019048C patent/NO2019048I1/no unknown
- 2019-12-24 JP JP2019232389A patent/JP2020073518A/ja active Pending
-
2020
- 2020-01-09 US US16/738,751 patent/US20200131271A1/en not_active Abandoned
- 2020-06-18 US US16/905,089 patent/US20200354464A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128771A patent/JP2022000424A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60235989D1 (de) | Antikörper gegen opgl | |
ATE471344T1 (de) | Antikörper gegen vla-1 | |
DE50204184D1 (de) | Espressobrüheinrichtung | |
DE60227724D1 (de) | Spülrohranordnung | |
PT1411764E (pt) | Cerca | |
ATE524462T1 (de) | C5-modifizierte indazolylpyrrolotriazine | |
DE50103741D1 (de) | Welle-Nabe-Verbindung | |
DE50204386D1 (de) | Kreuztransducer | |
ATE335486T1 (de) | Hydrazono-malonitrile | |
DE1319930T1 (de) | Coriolismassendurchflussmesser | |
NO20014597D0 (no) | Fremgangsmåte | |
EE200300569A (et) | CD44v6-spetsiifilised antikehad | |
DE60210848D1 (de) | Verbinder | |
DE50203412D1 (de) | Schwenkkolbenverdränger | |
DE50203984D1 (de) | Kugelgelenk | |
ATE355059T1 (de) | Isoxazolopyridinone | |
DE50201862D1 (de) | Messwandler | |
DE60221366D1 (de) | Verbinder | |
DE50203093D1 (de) | Losradlager | |
DE60233695D1 (de) | Verbinder | |
DE50202088D1 (de) | Garmodulsystem | |
DE50108179D1 (de) | Verbinder | |
DE50108381D1 (de) | Synchronisierschaltungsanordnung | |
DE10295006D2 (de) | Bauwerksabdichtung | |
ATA13992002A (de) | Schlackengranulierungsanlage |